AbbVie Inc. Stock
€138.60
Your prediction
AbbVie Inc. Stock
AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Pros and Cons of AbbVie Inc. in the next few years
Pros
Cons
Performance of AbbVie Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 1.600% | 5.159% | 4.525% | -11.854% | -8.912% | 55.906% | 79.883% |
| Biogen Inc. | 0.720% | 3.061% | 2.680% | -18.846% | -13.254% | 9.189% | -22.576% |
| Pfizer Inc. | 0.940% | 0.564% | -7.118% | -45.497% | -44.131% | -23.908% | -26.881% |
| Elanco Animal Health Inc. | 0.840% | 4.912% | 17.949% | 0.623% | 5.803% | -51.392% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Based on the provided financial statements, AbbVie Inc., a prominent company in the pharmaceutical industry, appears to be maintaining a strong financial position. The company has demonstrated consistent growth in revenues and net income over the years. However, there are also challenges in certain aspects that could impact the company's financial health.
Revenue growth: From 2020 to 2022, AbbVie's total revenues increased from €45.8 billion to $58.0 billion, signifying a healthy growth rate. This suggests a strong demand for their products and services in the pharmaceuticals industry.
Net income growth: Net income has shown a steady increase. In 2020, the net income stood at €4.6 billion, which rose to €11.5 billion in 2021 and further increased to $11.8 billion in 2022.
Comments
News
3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows
Are you looking for some quality dividend stocks to buy right now? When it comes to investing, it's often a good idea to check out those that haven't been doing too well lately and are trading near
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
These days, it seems like biotech buyout offers are falling from the sky. During the week ended Dec. 6, AbbVie (NYSE: ABBV) announced not one but two big acquisitions.
The pharma giant's latest big
Is AbbVie Stock a Buy Now?
Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. That's because it will need to become less reliant on Humira, its blockbuster